StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3029% above fair value
$704.23+6.21 (+0.89%)

Close on Nov 13, 2026Market cap $55.48BP/E 47.5Yield –

IDEXX Laboratories Inc grew revenue 11.9% to $4.66B over the twelve months to Sep 30, 2026. Operating income rose 15.3% to $1.51B, moving the operating margin from 31.3% to 32.3%. Free cash flow was $1.30B, up 35.3% from a year earlier. At the latest close the market valued the company at $55.48B, 47.5 times its earnings.

Revenue
$4.66B
+11.9% vs. a year earlier
Operating income
$1.51B
+15.3% vs. a year earlier
Free cash flow
$1.30B
+35.3% vs. a year earlier
EPS, diluted
$14.83
+17.6% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026

Valuation

Market cap
$55.48B
P/E ratio
47.5
Price to sales
11.90
Price to book
29.68
Dividend yield
–
Free cash flow yield
2.35%

Fundamentals

Revenue
$4.66B
Net income
$1.18B
EPS, diluted
$14.83
Free cash flow
$1.30B
Book value per share
$23.65
Diluted shares
79M

Trading

Next earnings
Feb 1, 2027 (estimated, before the open)
Previous close
$698.02
Open
$710.24
Day's range
$702.53 – $711.23
Volume
392,453
Average volume (20 days)
684,619
Index membership
S&P 500, Nasdaq-100, Russell 1000, Russell 3000
Beta (5 years)
1.17
52-week range
$500.61 – $769.98
RSI (14 days)
71.6
Volatility (1 year)
37.1%
Relative volume
0.66×
WACC
10.9%

On 2 of our idea lists: Quality compounders, Superinvestor favorites

Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2009, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodIDXXS&P 500DifferenceIDXX per yearS&P 500 per year
1 month+35.3%-3.0%+38.4 pts
3 months+24.2%-2.8%+27.0 pts
Year to date+4.1%+11.5%−7.4 pts
1 year+0.4%+13.5%−13.1 pts
3 years+62.9%+77.7%−14.8 pts+17.7%+21.1%
5 years+12.1%+72.6%−60.5 pts+2.3%+11.5%
10 years+545.1%+308.2%+236.9 pts+20.5%+15.1%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

$4.66B+11.9% YoY

Gross profit

$2.92B+13.7% YoY

Operating income

$1.51B+15.3% YoY

Net income

$1.18B+15.1% YoY

EPS, diluted

$14.83+17.6% YoY

Free cash flow

$1.30B+35.3% YoY
Reported periodTrailing twelve months

Press releases

Releases IDEXX Laboratories filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About IDEXX Laboratories

In Vitro & In Vivo Diagnostic Substances

IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary care, livestock, poultry, dairy, and water testing. Operating through its Companion Animal Group, Water quality products, Livestock, Poultry and Dairy, and human diagnostics segments, the company serves veterinarians, biomedical researchers, livestock producers, water utilities, and diagnostic laboratories. Its offerings include point-of-care analyzers, consumables, rapid assays, reference laboratory services, practice management software, diagnostic imaging, and microbiological water tests.

Company profile, executives and history

IDEXX Laboratories stock: common questions

What is IDEXX Laboratories's stock price?

IDXX closed at $704.23 on Nov 13, 2026, up 0.89% on the day. Over the past 52 weeks it traded between $500.61 and $769.98.

What is IDEXX Laboratories's market cap?

IDEXX Laboratories was worth $55.48B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

What is IDXX's P/E ratio?

IDXX trades at 47.5 times earnings, based on diluted earnings per share of $14.83 over the twelve months to Sep 30, 2026.

How much revenue does IDEXX Laboratories make?

IDEXX Laboratories reported revenue of $4.66B for the twelve months to Sep 30, 2026, up 11.9% from a year earlier.

Does IDEXX Laboratories pay a dividend?

No. IDEXX Laboratories has not paid a cash dividend over the last twelve months.

When does IDEXX Laboratories report earnings next?

IDEXX Laboratories is expected to report Q4 FY2026 results on Feb 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has IDXX stock performed over the past year?

Including dividends, IDXX returned +0.4% over the past year, against +13.5% for the S&P 500.

How many IDXX shares are sold short?

2M shares were sold short at the latest FINRA report, 3.00% of the float, or 4.5 days of average trading volume.

Who are IDEXX Laboratories's competitors?

Companies most similar to IDEXX Laboratories by business, industry and size include QDEL, NEOG, ELAN, LNTH, ZTS.

See a number that looks wrong?